Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $107.10 | Total: $535.50 |
| 1 | 10 | $90.72 | Total: $907.20 |
| 1 | 25 | $76.86 | Total: $1,921.50 |
| 1 | 50 | $65.52 | Total: $3,276.00 |
| 1 | 100 | $56.70 | Total: $5,670.00 |
Overview
Sivopixant (S-600918) (S-600918) is a potent and selective antagonist of P2X3 receptor (P2X3 IC 50 =4.2 nM; P2X23 IC 50 =1100 nM). Sivopixant shows strong analgesic effect .
Chemical Properties
| Molecular Formula | C25H22ClN5O5 |
| Molecular Weight | 507.93 |
| CAS Numbers | 2414285-40-6 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | C(N1C(=NC2=CC=C(OC3=CC=CC=N3)C=C2)NC(=O)N(C[C@@H](C(O)=O)C)C1=O)C4=CC=C(Cl)C=C4 |
Storage and Handling
0C Short Term, -20C Long Term
References
Kai H, et al. Discovery of clinical candidate Sivopixant [S-600918] Lead optimization of dioxotriazine derivatives as selective P2X3 receptor antagonists [published online ahead of print, 2021 Sep 26]. Bioorg Med Chem Lett. 2021;52 128384.